The unknown impact of the allelic and gene dosage effects and fate of mutant uromodulin leaves open the gap between postulated gain‐of‐function mutations, end‐organ damage and disease progression in ADTKD. Here, UMOD is linked to autosomal dominant medullary cystic kidney disease with or without hyperuricemia.